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ABSTRACT
Atypical femoral fractures (AFFs) are uncommon and have been associated particularly with long-term antiresorptive therapy,
including bisphosphonates. Although the pathogenesis of AFFs is unknown, their identiﬁcation in bisphosphonate-na€ıve
individuals and in monogenetic bone disorders has led to the hypothesis that genetic factors predispose to AFF. Our aim was to
review and summarize the evidence for genetic factors in individuals with AFF. We conducted structured literature searches and
hand-searching of conference abstracts/reference lists for key words relating to AFF and identiﬁed 2566 citations. Two
individuals independently reviewed citations for (i) cases of AFF in monogenetic bone diseases and (ii) genetic studies in
individuals with AFF. AFFs were reported in 23 individuals with the following 7 monogenetic bone disorders (gene): osteogenesis
imperfecta (COL1A1/COL1A2), pycnodysostosis (CTSK), hypophosphatasia (ALPL), X-linked osteoporosis (PLS3), osteopetrosis,
X-linked hypophosphatemia (PHEX), and osteoporosis pseudoglioma syndrome (LRP5). In 8 cases (35%), the monogenetic bone
disorder was uncovered after the AFF occurred. Cases of bisphosphonate-na€ıve AFF were reported in pycnodysostosis,
hypophosphatasia, osteopetrosis, X-linked hypophosphatemia, and osteoporosis pseudoglioma syndrome. A pilot study in
13 AFF patients and 268 controls identiﬁed a greater number of rare variants in AFF cases using exon array analysis. A whole-
exome sequencing study in 3 sisters with AFFs showed, among 37 shared genetic variants, a p.Asp188Tyr mutation in the GGPS1
gene in the mevalonate pathway, critical to osteoclast function, which is also inhibited by bisphosphonates. Two studies
completed targeted ALPL gene sequencing, an ALPL heterozygous mutation was found in 1 case of a cohort of 11 AFFs, whereas
the second study comprising 10 AFF cases did not ﬁnd mutations in ALPL. Targeted sequencing of ALPL, COL1A1, COL1A2, and
SOX9 genes in 5 cases of AFF identiﬁed a variant in COL1A2 in 1 case. These ﬁndings suggest a genetic susceptibility for AFFs.
A large multicenter collaborative study of well-phenotyped AFF cases and controls is needed to understand the role of genetics
in this uncommon condition. © 2017 The Authors JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for
Bone and Mineral Research.
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Introduction
There is currently a crisis in the treatment of osteoporosis,with a call to action by multiple international professional
societies to aggressively reduce fracture risk in our aging
population.(1) Despite the availability of effective antiresorp-
tive osteoporosis drugs, namely bisphosphonates and deno-
sumab, treatment rates after hip fracture—in patients at the
highest risk for subsequent fractures—have halved from 40%
in 2002 to 21% in 2011.(1) This crisis is driven by in large part by
fear of rare complications of antiresorptive drugs, such as
atypical femoral fractures (AFFs) (Fig. 1).(2,3) Despite the
signiﬁcant burden of osteoporosis and fractures globally,
since the ﬁrst clinical reports of bisphosphonate-associated
AFFs in 2005(4) and the subsequent FDA safety report in
2010,(5) there has been a 50% decline in the use of these
effective osteoporosis therapies.(6)
Currently, the pathogenesis of AFFs is not known, but AFFs
have also been described in individuals with monogenetic bone
disorders and can occur in bisphosphonate-na€ıve individuals,
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who comprise about 7% of cases.(2,3) As such, it is likely that
genetic variants exist that predispose to AFFs. This article
reviews and summarizes the evidence for genetic factors in
individuals with AFFs after ﬁrst discussing the epidemiology and
clinical problem of this condition.
Osteoporosis and anti-osteoporosis drugs
Osteoporosis is a condition with reduced bone strength due to
abnormalities in the material composition andmicrostructure of
bone predisposing to fractures. Hip fractures are catastrophic
events resulting in chronic pain, disability, and increased
mortality up to 35% within 12 months.(7) Bisphosphonates are
well-established drugs for the management of osteoporosis.
They are effective at reducing the risk of vertebral fractures by up
to 70%(8) and also reduce nonvertebral and hip fractures.(9) They
have been approved treatments for osteoporosis for more than
2 decades.
Bisphosphonates are structural analogs of inorganic pyro-
phosphate and inhibit bone resorption by binding avidly to
bone mineral surfaces, are subsequently internalized by bone-
resorbing osteoclasts, whereby they disrupt various biochemical
processes.(10) In particular, nitrogen-containing bisphospho-
nates inhibit farnesyl pyrophosphate synthase, a key enzyme in
the mevalonate pathway. This pathway is important for the
biosynthesis of isoprenoids, molecules essential for multiple
cellular processes. Disruption of this pathway affects osteoclast
function and viability, ultimately resulting in reduced bone
resorption.
The problem of atypical femoral fractures
In 2005, Odvina and colleagues published the ﬁrst case series of
femoral shaft fractures associated with long-term bisphospho-
nate use and showed evidence of markedly suppressed bone
formation on a bone biopsy.(4) A subsequent series of femoral
fractures from Singapore in 2007(11) emphasized the unusual
location of this fracture in the subtrochanteric region. This
region (from just distal to the lesser trochanter to just proximal
to the supracondylar ﬂare of the femur) is notably resilient to
traumatic injuries.(12) In 2010, the ASBMR convened an
international Task Force to commission a report on and to
create a case deﬁnition of AFF.(2) This case deﬁnition was
subsequently revised in 2013 (Table 1).(3)
Epidemiology and consequences of AFFs
In a population-based Swedish study including 12,777 women
aged 55 years with femoral fractures, 59 AFFs were identiﬁed,
of which 46 occurred in bisphosphonate users.(13) Linkage to the
Swedish Prescribed Drug Register identiﬁed that 46 AFFs
occurred in 83,311 women ever prescribed bisphosphonates
in the preceding 3 years, whereas only 13 cases of bi-
sphosphonate-na€ıve AFFs occurred out of 1,437,820 Swedish
women aged 55 years who were not prescribed bisphosph-
onates. The age-adjusted relative risk of AFF with any use of
bisphosphonates was 47.3.
Meier and colleagues found that the proportion of patients
exposed to bisphosphonates was higher in patients with AFFs
Fig. 1. X-ray series of a 61-year-old woman with postmenopausal osteoporosis presenting with prodromal left thigh pain in the setting of 11 years of
alendronate therapy. An initial radiograph of the left femur demonstrated a transverse midshaft lateral stress fracture consistent with an incomplete
atypical femoral fracture (A). After a minimal trauma fall, the fracture progressed to a complete fracture (B), and this required surgical ﬁxation with an
intramedullary nail (C). Reproduced from Nguyen et al. Bone Rep. 2017;6:34–7.
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than in those with non-atypical fractures (82.1% versus 6.4%).(14)
The risk of AFF increases with longer duration of bisphospho-
nate exposure (1.8 per 100,000 cases per year after 0.1 to
1.9 years, rising to 113.1 per 100,000 cases per year for 8.0 to
9.0 years of use).(15) AFFs are also associated with a younger
cohort,(16) Asian ethnicity,(17) a previous stress fracture of the
contralateral femur,(14) and glucocorticoid use.(2)
Although the incidence of AFF is relatively low, the effect of a
painful, spontaneous femoral fracture is devastating to the
individual. In addition, up to 40% of AFFs occur in bilateral
femora and delayed healing is common, resulting in prolonged
immobilization. Prodromal pain occurs in more than 70%.(2)
Pathophysiology: proposed mechanisms
Although the pathogenesis of AFFs remains largely unknown, its
epidemiological associationwith bisphosphonate therapy led to
several proposed mechanisms. Bisphosphonates alter collagen
maturity and cross-linking, as indicated by the increase in
pyridinoline (PYD)/deoxypyridinoline (DPD) ratio, increasing the
strength but also stiffness of bone.(18,19) Moreover, reducing
bone remodeling also increases pentosidine, which interacts
with collagen through oxidative nonenzymatic cross-linkage,
leading to advanced glycation end product accumulation, which
results in reduced toughness. Both effects increase matrix
stiffness and consequently reduce the peak-tolerated strain. The
stiffening by increased matrix mineralization and pentosidine
cross-linking reduces ductility; the structure becomes more
brittle.(20,21)
Also, more homogeneouslymineralized bone tissue facilitates
fracture crack initiation and propagation.(22,23) Thus, remodeling
suppression increases microfracture burden, allowing cracks to
lengthen and reducing crack removal.(24,25) Microdamage
accumulation may be further compounded by the preferential
uptake of bisphosphonates at sites of high bone remodeling,
including sites of stress fractures. Therefore, by suppressing
remodeling at these local sites, bisphosphonates could
potentially affect the intracortical repair of a developing stress
fracture such as an AFF, allowing crack progression to a
complete fracture.
Iliac crest bone biopsies fromAFF cases showed reduced bone
turnover in most cases, as would be expected with bi-
sphosphonate treatment, but this has not been a universal
ﬁnding.(2) In bone biopsies obtained close to the fracture site in
AFF cases, both decreased and increased bone remodeling have
been described, although the latter may be inﬂuenced by the
recent fracture and may not be indicative of the underlying
pathogenic mechanism of AFFs.
Hypotheses and aims
The rarity of AFFs amongst the millions of bisphosphonate users
worldwide is suggestive of an individual susceptibility, which
could be an underlying genetic predisposition.
The potential importance of genetic factors is supported by
the occurrence of AFFs in bisphosphonate-na€ıve individu-
als.(13,26,27) Some of these bisphosphonate-na€ıve individuals
were found to have an underlying monogenetic bone disease,
such as hypophosphatasia, pycnodysostosis, osteopetrosis,
X-linked hypophosphatemia (XLH), and osteoporosis pseudo-
glioma syndrome (OPPG), leading to the hypothesis that
carriers of pathogenic mutations (very rare variants) or
polymorphisms (common variants) in genes related to these
monogenetic bone diseases may predispose to AFFs. Mild
unrecognized forms of such heritable bone diseases may
underlie the etiology of AFFs in some patients. Additionally,
AFFs have been reported in patients with osteogenesis
imperfecta (OI) and X-linked osteoporosis based on a PLS3
mutation. Yet these cases may be related to the coexistent
antiresorptive treatment rather than the underlying genetic
condition, and no analysis has ever been done to investigate
whether AFFs occur more frequently in patients with these
genetic bone disorders. Even more suggestive of a genetic
background of AFFs is the identiﬁcation of 2 families with
multiple family members with AFF.(28,29)
Furthermore, racial differences in risk and site of AFFs exist,
which may be consistent with a genetic background. The age-
adjusted relative risk for AFFs in Asians is 6.6 compared with
white women corrected for current bisphosphonate use and
duration of bisphosphonate treatment.(17) Schilcher and col-
leagues showed ethnic differences in location of the AFFs, with
fractures mainly occurring in the subtrochanteric region in
Singapore, compared with diaphyseal in Sweden.(30) The
differences may be related to femoral geometric parameters
that are more common in Asian women, such as increased
femoral bowing and smaller neck-shaft angles.(31–34) Increased
femoral curvature may lead to an altered distribution of loading
with more tensile strain on the lateral side and more
compression on the medial side of the femur. This imbalance
of biomechanical stresses with increased femoral bowing might
Table 1. ASBMR TASK Force Revised Case Deﬁnition of AFFs
AFF must be located along the femoral diaphysis from just distal to the lesser trochanter to just proximal to the supracondylar flare.
At least four of five Major Features must be present. No Minor Features are required.
Major features
 Minimal or no trauma as in a fall from a standing height or less
 The fracture line originates at the lateral cortex and is transverse, although it may become oblique as it progresses medially
 Complete fractures extend through both cortices and may be associated with a medial spike; incomplete fractures involve only the
lateral cortex
 The fracture is non- or minimally comminuted
 Localized periosteal or endosteal thickening of the lateral cortex is present at the fracture site (“beaking” or “ﬂaring”)
Minor features
 Generalized increase in cortical thickness of the femoral diaphyses
 Unilateral or bilateral prodromal symptoms such as dull or aching pain in the groin or thigh
 Bilateral incomplete or complete femoral diaphysis fractures
 Delayed fracture healing
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contribute to spontaneous, transverse femoral fractures such as
AFFs.(35)
We speculate that genetic factorsmay also interactwith clinical
risk factors for AFFs, including a high number of comorbid
conditions, and concomitant medications, like glucocorticoids.(2)
The aim of this systematic review is to gather the data of AFF
in relation to genetics and scrutinize the available evidence of
genetic risk factors underlying the susceptibility for AFFs and to
inform future directions for further research.
Methods
We conducted a structured literature search of electronic
databases, including Embase, Medline, Web of Science,
Cochrane Central, and Google Scholar, and hand-searching of
conference abstracts/reference lists using the following key
words: femur/femoral fracture or subtrochanteric fracture,
atypical and drug-induced disease, bisphosphonates, antire-
sorptives, and denosumab.
We identiﬁed 2566 citations, and authors HHN and DMvdL
independently reviewed citations with the following inclusion
criteria: (i) cases of AFFs in monogenetic bone diseases, and
(ii) genetic studies in individuals with an AFF. Articles were only
included if images of the femoral fracture were published and
fulﬁlled the ASBMR case deﬁnition (Table 1) or if the authors
used the recent ASBMR case deﬁnition to deﬁne the presence of
AFFs. Twenty-six citations fulﬁlled the inclusion criteria and are
described below. During preparation of this manuscript, two
additional published articles and a conference abstract relevant
to this topic were identiﬁed and also included in this review,
making a total of 29 included studies.
Results and Discussion
Reports of AFFs occurring in monogenetic bone
disorders
Subtrochanteric femoral fractures fulﬁlling the ASBMR case
deﬁnition of AFF were identiﬁed in 7 monogenetic bone
disorders. These ﬁndings are summarized in Table 2 and
explored further below.
The 7 bone disorders included primary defects in bone
mineralization, bone remodeling, collagen synthesis and struc-
ture, and osteocyte function (Fig. 2). AFFs were also reported in
juvenile forms of osteoporosis linked with long-term bisphosph-
onate use and may reﬂect a pediatric variant of bisphosphonate-
associated AFF. These cases provide insight into the possible
pathogenesis of AFFs and indicate potential candidate genes that
may encode for variants predisposing to AFF. When dealing with
bisphosphonate-na€ıve patients with AFFs, clinicians may need to
carefully consider and exclude these underlying genetic
conditions in their diagnostic assessment for secondary causes
of skeletal fragility.
Mineralization defect
Hypophosphatasia: The literature search identiﬁed 4 cases of
AFFs occurring in adult hypophosphatasia,(36–39) in all of whom
the genetic condition was unmasked after the femoral fracture.
Three cases were bisphosphonate-na€ıve and in 1 case, reported
by Sutton and colleagues, of bilateral atraumatic AFFs occurred
simultaneously in a postmenopausal woman after 4 years of
bisphosphonate therapy for osteoporosis.(38)
Hypophosphatasia is an inborn error of metabolism
characterized by low alkaline phosphatase (ALP) levels, due
to a loss-of-function mutation in the ALPL gene (also known as
TNSALP gene) that encodes the tissue nonspeciﬁc ALP.(40) This
defect in enzyme function leads to accumulation of substrates,
such as inorganic pyrophosphate, pyridoxal 5’ phosphate
(active form of vitamin B6), and phosphoethanolamine.
Inorganic pyrophosphate is an inhibitor of mineralization,
and its accumulation in hypophosphatasia results in skeletal
and dental manifestations.
The clinical spectrum of hypophosphatasia is broad
and can range from severe lethal forms in infancy to mild
forms in adulthood or with only dental complications
(odontohypophosphatasia).(40) Skeletal manifestations in
adulthood may include osteopenia, poorly healing stress
fractures of the metatarsal bones, and pseudo-fractures.
The pseudo-fractures commonly occur on the lateral side of
the femoral shaft and can resemble bisphosphonate-
associated AFFs.(41)
Table 2. List of Monogenetic Bone Disorders Associated With Atypical Femoral Fractures (AFFs)
Monogenetic bone
disorder
Genes associated
with disorder Sex Age (yrs)
Bilateral AFF
n
BP exposure
n
Disorder diagnosed
following AFF
n
Hypophosphatasia(36–39) ALPL 4 F 50–55 4 1 4
XLH(41) PHEX 1M 27 0 0 0
Pycnodysostosis(44–49) CTSK 3M/4 F 23–55 3 0 2
Osteopetrosis(51–53) TCIRG1, CLCN7,
OSTM1, PLEKHM1,
SNZ10, TNFS11,
TNFRSF11A, CA11
4 F 21–56 2 0 1
OPPG(57) LRP5 1M 38 0 0 1
OI(61–65) COL1A1/1A2, CRTAP,
LEPRE1, PPIB,
SERPINH1, FKBP10,
PLOD2, SP7
4 F/1M 11–75 2 5 0
X-linked osteoporosis(70) PLS3 1M 18 0 1 0
AFF¼ atypical femoral fracture, F¼ female, M¼male, BP¼bisphosphonate, XLH¼X-linked hypophosphataemia, OPPG¼ osteoporosis pseudo-
glioma syndrome, OI¼ osteogenesis imperfect.
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The similarity in the pseudo-fractures found in hypophos-
phatasia and the AFFs that occur in patients with osteoporosis
treated with bisphosphonates may be explained by the fact that
bisphosphonates are synthetic analogs of inorganic pyrophos-
phate resistant to ALP activity. There has been one case report of
pyrophosphate accumulation at a site of a bisphosphonate-
associated AFF.(42) Alternatively, the presence of AFFs found in
bisphosphonate-na€ıve patients with hypoposphatasia may
suggest that variants in the ALPL gene may be implicated in
the pathogenesis of AFFs, independent of bisphosphonate
exposure. Speculation also exists as to whether bisphosphonate
therapy in individuals withmild forms of hypophosphatasia may
precipitate AFFs. Targeted genetic testing of the ALPL gene in
small cohorts of individuals with AFF have been conducted, and
results will be described further below.
X-linked hypophosphatemia (XLH): Whyte and colleagues
reported that pseudo-fractures in the lateral cortex of the
femoral shaft can occur in XLH similar to AFFs.(41) In this report, a
27-year-old bisphosphonate-na€ıve male with XLH had radiolog-
ical features of an incomplete AFF.
XLH is the most common form of hereditary rickets and is
caused by loss-of-function mutations of the PHEX gene.(43)
Biochemical ﬁndings in this condition are hypophosphatemia
with renal phosphate wasting and associated inappropriately
low 1,25-hydroxyvitamin D levels and high FGF-23 levels. Low
bone mineral density, rickets, and/or osteomalacia with
shortening and deformities of the lower limbs are common
features of this condition.
Defect in bone remodeling
Pycnodysostosis: Subtrochanteric femoral fractures fulﬁlling
criteria for AFFs have been described in 7 adult cases of
pycnodysostosis. In 3 of these cases, pycnodysostosis was
unmasked after the femoral fracture.(44–49) Five cases were
bisphosphonate-na€ıve, whereas prior bisphosphonate use was
unknown in the remaining 2 cases. Bilateral AFFs occurred in 4
cases of pycnodysostosis. Nakase and colleagues(45) reported
delayed healing of the femoral shaft fracture of up to 3 years in 2
patients with pycnodysostosis.
Pycnodysostosis is a rare, autosomal recessive disorder of
osteoclast function, characterized by short stature, osteoscle-
rosis, pathological fractures with poor healing, acro-osteolysis of
the terminal phalanges, and craniofacial dysmorphisms.(50) It is
caused by mutations in the CTSK gene resulting in deﬁciency of
cathepsin K activity. Cathepsin K is an enzyme that is highly
expressed in osteoclasts and is responsible for degradation of
bone matrix proteins during osteoclast-mediated bone resorp-
tion. The defect in osteoclast activity leads to osteosclerosis,
increased bone density, abnormal bone matrix, and brittle
bones, predisposing to pathological fractures of the long bones.
Pycnodysostosis is managed symptomatically, and antiresorp-
tive therapy has no place/is not indicated in this condition. The
occurrence of AFFs in the absence of bisphosphonate use in
pycnodysostosis, as described in these case reports, raises the
possibility that genetic variants of the CTSK gene may
predispose individuals to AFF.
Fig. 2. Genes implicated in atypical femoral fractures and their relationship to bone remodeling and bone matrix. HSC¼hematopoietic stem cell;
MSC¼mesenchymal stem cell.
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Osteopetrosis: Our literature search identiﬁed 4 cases of AFFs
occurring in bisphosphonate-na€ıve individuals with osteopet-
rosis, although the underlying mutated gene was not reported
in these articles.(51–53) All authors described the surgical
difﬁculties in the repair of the subtrochanteric femoral fractures
in sclerotic bone.
Osteopetrosis is a class of rare heterogeneous genetic
disorders characterized by high bone mass due to a failure of
osteoclast-mediated bone resorption.(54) Mutations in 8 genes
have been described, including TCIRG1, OSTM1, PLEKHM1,
SNZ10, TNFSF11, TNFRSF11A, CAII, and CLCN7. Despite increased
bone density, the sclerotic bone is brittle and fragility fractures
occur,(55) and antiresorptive therapies are avoided in this
condition. Other clinical features include craniofacial deformi-
ties, neurological compression from sclerotic bone, bone
marrow failure due to reduction of bone marrow space,
complications from extramedullary hematopoiesis, osteoarthri-
tis, and dental complications.
Osteoporosis pseudoglioma syndrome (OPPG): OPPG is a rare,
autosomal recessive form of juvenile osteoporosis caused by a
loss-of-function mutation in the LRP5 gene.(56) We identiﬁed a
single case report of an AFF occurring in a 40-year-old
bisphosphonate-na€ıve male with OPPG, who had multiple
fragility fractures since childhood and evidence of low bone
turnover on bone biopsy.(57) This is the only report of an AFF
occurring in a genetic condition with primary osteoblast
dysfunction. LRP5 acts through the osteoblastic Wnt/b-catenin
canonical signaling pathway to regulate bone formation.(56)
Homozygous and compound heterozygous loss-of-function
mutations in LRP5 result in OPPG, whereas gain-of-function
mutations in LRP5 results in high bone mass. Common
polymorphisms of LRP5 can affect bone density in the general
population.(58)
Defect in collagen synthesis and structure
Osteogenesis imperfecta (OI): OI is a heterogeneous, heritable
connective tissue disorder with prominent skeletal features,
including low bone mass, hypermineralized bone matrix,
multiple fragility fractures, bone deformities, and short stat-
ure.(59) Bisphosphonates are widely used therapies in children
and adults with this condition. However, in a recent Cochrane
Review of bisphosphonate use in OI, the authors concluded that
although bisphosphonates may improve bone mass, the
evidence for long-term fracture reduction is unclear.(60)
To date, 4 case reports have been published describing
classical AFFs in adults with OI.(61–64) All cases had prior
bisphosphonate exposure. Vasanwala and colleagues reported
bilateral AFFs in an 11-year-old female with OI after 5 years of
pamidronate therapy,(65) representing the only reported case of
classical AFFs occurring in a pediatric patient with OI.
Hegazy and colleagues published a case series of AFF
occurring in 6 pediatric OI patients,(66) who all had prior
long-term bisphosphonate therapy. However, the stress
fractures occurred at periprosthetic sites and would
technically be excluded from the ASBMR case deﬁnition.
The occurrence of bisphosphonate-associated AFF in chil-
dren raises the question of long-term safety of these drugs in
pediatric populations.
A retrospective study by Nicolaou and colleagues demon-
strated that a different pattern of femoral shaft fractures
occurred in patients with OI and bisphosphonate use compared
with a historical cohort of OI patients without bisphosphonate
therapy, with more fractures occurring in the proximal third of
the femur in children treated with bisphosphonates, whereas
mid-diaphyseal femoral fractures were more common in a
control group without bisphosphonate exposure.(67)
OI is most often caused by defects in type 1 collagen synthesis
(encoded by COL1A1 and COL1A2 genes), resulting in aberrant
protein posttranslational modiﬁcation, folding, intracellular
transport, and bone matrix incorporation.(68) This either results
in collagen protein deﬁciency or mutant collagen protein
synthesis and leads to abnormal composition and organization
of bone matrix, which increases bone stiffness and skeletal
fragility.
Mice models suggest that skeletal microdamage levels are
increased in OI, resulting in higher bone remodeling activity to
target microcrack repair.(69) As bisphosphonates suppress bone
remodeling and may impede microcrack repair, its use in
patients with OI may result in even higher levels of micro-
damage accumulation and compromised bone toughness,
predisposing to stress fracture development and AFF.
Although bisphosphonate treatment has been used to
improve bone density in OI, they do not reverse the underlying
impaired collagen defect. AFFs have been described in adult
cases with OI and bisphosphonate exposure, whereas the risk of
AFFs and the long-term safety of bisphosphonate use in
pediatric populations remains unclear.
Defect in osteocyte function
X-linked osteoporosis: Our group has published a case report on
an AFF occurring in an 18-year-old male with X-linked
osteoporosis who had been treated with bisphosphonates for
9 years.(70) X-linked osteoporosis is a form of juvenile osteopo-
rosis caused by pathogenic variants in PLS3, located on the X
chromosome, encoding for the protein plastin 3.(71) Mutations in
this gene have been associated with skeletal fragility in
hemizygous males, whereas the clinical phenotype of heterozy-
gous females may vary, ranging from normal bone mineral
density and an absence of fractures to early-onset osteoporosis.
Affected individuals can present in childhood with low bone
density, vertebral compression fractures, and long bone
fractures.(72) Although the exact mechanism through which
PLS3 mutations cause skeletal manifestations is unclear,
decreased mechanosensing of osteocytes was proposed.(71)
This is supported by a recent ﬁnding of altered osteocyte protein
expression in low-turnover osteoporosis caused by mutations in
WNT1 and PLS3.(73) Similar to bisphosphonate use in pediatric
cases of OI discussed previously, this case report of a
bisphosphonate-associated AFF in an adolescent raises the
concern of long-term safety of these agents in children.
Candidate gene studies
Three studies have been conducted to search for variants in
selected genes in patients with AFFs. All 3 studies included ALPL
mutation analysis, with 1 study also including COL1A1, COL1A2,
and SOX9 genes (Table 3).
Because inorganic pyrophosphate is a structural analog of
bisphosphonates and femoral fractures with atypical features
occur in cases of hypophosphatasia without prior antiresorp-
tive therapy, it has been hypothesized that this condition is a
genetic risk factor for AFF. The exact prevalence of mutations
in the ALPL gene in the general population is unknown, but in
the European population, it is estimated that the prevalence of
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mild forms of hypophosphatasia is 1:6300.(74) Carriers of
mutations in the ALPL gene with a mild phenotype may be
asymptomatic.
At the annual meeting of the ASBMR in 2013, an abstract was
presented by Sum and colleagues(75) on prospective ALPL
analysis in 11 patients with bisphosphonate-associated AFFs. All
coding exons and adjacent splice sites were sequenced in these
individuals. In 1 patient, a single mutation was found affecting
the donor splice site in exon 6 that is reported in lethal infantile
hypophosphatasia when associated with a second missense
mutation on the other chromosome.(76) The patient was a
66-year-old woman with ALP levels between 33 and 40U/L
(range 35 to 129U/L) while on bisphosphonate therapy. Bone
mineral density was in the osteopenic range. Vitamin B6 status
was not reported. The conclusion of this ﬁnding was that
mutations of ALPL associatedwith subclinical hypophosphatasia
may rarely result in bisphosphonate-associated AFFs.
In 2016, Bhattacharyya and colleagues(77) published on a
retrospective case-control study that investigated hypophospha-
tasia as a risk factor for AFFs. Controls (n¼ 13) without anAFF had
used bisphosphonates for at least 5 years. Patients (n¼ 10) had
sustained a complete AFF while using bisphosphonates, and 3
patients were continuing bisphosphonate treatment. In both
patients and controls, a standardized history, physical exam, and
standing long leg radiographs were performed. Additionally,
levels of ALP and pyridoxal 5’ phosphate were measured.
Participants withheld vitamin supplementation for at least
1 week before the blood test because this can affect pyridoxal
5’ phosphate levels. DNA testing was performed in all patients
with AFF (n¼ 10). Because of the high costs of genetic testing,
analysis ofALPLwas only performed in the controlswhohad low(-
normal) serum ALP levels <60U/L, which was found in 9 of 13.
Serum ALP <50U/L was considered abnormal in this study.
Mean ALP levels in AFF patients and controls were 58U/L
(range 37 to 73) and 56U/L (38 to 74), respectively. Five of 10 AFF
cases (50%) had an ALP level <50U/L versus 5 of 13 controls
(38%). Despite cessation of vitamin supplementation, pyridoxal 5’
phosphate levelwas elevated in2 controlswith lowALPwhoused
multivitamins on a regular basis. No mutations of the ALPL gene
were found in either the AFF patients or controls. Four different
coding variants in the ALPL gene were found in patients and
controls, whichhad an allele frequency of 0.1 or higher in a cohort
with 4300 European American samples (Exome Variant Server,
NHLBI GO Exome Sequencing Project (ESP), Seattle, WA, USA).
Rare variants are usually deﬁned by a minor allele frequency
(MAF)<0.01, whereas variants with a MAF >0.05 are considered
common and less common variants have a MAF of 0.01 to 0.05.
The 4 coding variants were found in equal frequencies in the
AFF group versus the control group; rs1780316 (1.00 versus 0.94),
rs3200254 (0.20 versus 0.17), rs3200255 (0.2 versus 0.17), and
rs34605986 (0.10 versus 0.00). A post hoc analysis revealed that in
this study a 40% prevalence of ALPL mutations in AFF patients
would have been needed to detect a difference with 80% power.
These results suggest that the low ALP levels in this study
population are most likely related to antiresorptive treatment
rather than an underlying mild form of hypophosphatasia.
In this study, no evidence was found for hypophosphatasia as
a risk factor for AFFs. However, considering the small sample size
and ensuing lack of power in this study,ALPL cannot be ruled out
as a potential susceptibility gene based on these results.
In a study by Funck-Brentano and colleagues in 2016,(78) the
ALPL, COL1A1, COL1A2, and SOX9 genes were sequenced in 4
females and 1male with AFF. Fourteen AFF cases were identiﬁed
by reviewing radiographs of patients with femoral fractures in
three academic hospitals in France between 2007 and 2010, but
only 5 patients gave consent for genetic testing. The rationale
for ALPL and COL1A1/1A2 testing in AFFs has been discussed
above. SOX9 plays a role in chondrocyte differentiation and
regulation of the anti-Mullerian hormone (AMH). Mutations in
this gene are associated with campomelic dysplasia, a syndrome
characterized by skeletal malformations and sex reversal.
One patient carried a heterozygous missense mutation in
COL1A2 that was found in the NHLBI GO Exome Sequencing
Project (ESP) with a MAF of 0.0008 (rs72658163; c.2123G>A;p.
Table 3. Genetic Studies in AFF Cohorts and Their Findings
Author, year
Cases of
AFF, n Genetic analysis Major findings
Roca-Ayats et al. 2017(28) 6 (3 sisters) Wholeexome sequencing 37 rare mutations in 34 genes were identified,
including: GGPS1, CYP1A1, MVD, FN1, SYDE2, NGEF
(The remaining 28 genes were not published)
Lau et al. 2017(29) 2 sisters Whole exome sequencing Novel rare homozygous variant in CTSK gene
(C.784þ 3A>C) was identified.
Perez-Nunez et al. 2015(80) 13 Exon array analysis Rare variants were more common in AFF cases
compared to a control group (n¼ 268), and
several rare variants tended to accumulate in
AFF cases.
Variants in 20 genes associated with AFF were
identified: PPEF2, ACOXL, GGA3, LIPN, DOCK2,
CCDC147, OR51T1, PCK2, CRYBB2, CXCR7, EDC3,
SF3B3, SLC15A5, SLC2A6, FOXK2, CNGB1,
NAT8B, HHAT, OR2L13, SYTL2
Funck-Brentano et al. 2016(78) 5 ALPL, COL1A1,
COL1A2, SOX9 gene
sequencing
Heterozygous mutation in COL1A2 (c.213G>A; p.
Arg708GIn) in 1 case
Bhattacharyya et al. 2016(77) 10 ALPL gene sequencing No mutations found
Sum et al. 2013(75) 11 ALPL gene sequencing Heterozygous mutation in ALPL gene
(c.648þ 1G>A) in 1 case
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Arg708Gln). Apart from short stature (146 cm), the 78-year-old
patient had no speciﬁc physical features of OI. Vertebral fracture
status in this patient is not reported. She also had a single
nucleotide polymorphism (SNP) in the ALPL gene that does not
alter the protein (rs370212283; MAF 0.0002 in ESP). She had used
risedronate for at least 5 years. The potential pathogenicity of the
missense variant in COL1A2 is unclear. Initially it was regarded as a
pathogenic variant in Marfan syndrome or OI. However, because
this variant was also found in unaffected or mildly symptomatic
family members, it was later considered not clinically relevant or
possibly a genetic modiﬁer, having small effects on the expression
level of other, disease-causinggenes. In cultured dermalﬁbroblasts
of two unrelated heterozygous carriers of this variant, the diameter
of the collagen ﬁbrils was approximately 20% of control collagen
ﬁbrils.(79) This may imply that this variant affects connective tissue
structure and is possibly involved in collagen-related disorders.
In another patient, six common variants of the ALPL gene
were detected, including a nonprotein-altering variant, present
in the Exome Aggregation Consortium (ExAC) with a MAF of
0.17 or higher (rs3200254; rs2275377; rs2275376; rs74063111;
rs75829132; rs3200255). Another patient had a different
nonprotein-altering variant in the ALPL gene (rs3200256; MAF
0.01 in ExAC). In 2 patients, no genetic variants were found. No
variants were found in COL1A1 and SOX9.
Although this was a small cohort study, genetic testing of 4
genes identiﬁed a previously reported mutation in COL1A2 and
common variants in the ALPL gene, supporting the hypothesis
that AFF populations are enriched with variants in genes
associated with monogenetic diseases.
Exon array analysis
In a pilot study, Perez-Nu~nez and colleagues(80) conducted an
exon array analysis (Affymetrix Axion 2.0 exome array) in 13
women with AFFs and 268 controls that consisted of healthy
women (n¼ 87) and patients with postmenopausal osteoporo-
sis without AFFs (n¼ 181) (Table 3). By including the osteopo-
rosis patients in the control group, the investigators intended to
avoid the ﬁnding of osteoporosis-related variants rather than
variants associated with AFFs. The analysis was restricted to
variants with a minor allele frequency<0.03 in the overall study
population. Twenty-one SNPs in 20 genes were deﬁned as risk
variants based on the arbitrary threshold of a p value < 0.0025.
However, only one variant remained statistically signiﬁcant after
correction for multiple testing, a missense variant in the PPEF2
gene, which has no known function in bone metabolism. The
distribution of these less common variants in cases and controls
was statistically signiﬁcantly different. In 12 of 13 AFF cases,
three or more risk variants were present. In 15.7% (n¼ 42) of the
control group, one risk variant was present, but none of the
controls had more than one risk variant. The genes involved are
not linked to known bone disorders, although the authors
suggested that a possibly damaging missense variant in the
HHAT gene, belonging to the hedgehog protein family, may be
connected to developmental bone defects, while another
possibly damaging missense variant in the CXCR7 gene (also
known as ACKR3) modulates the activity of precursor osteo-
blasts. These ﬁndings indicate that several variants combined
may be associated with (a higher risk of) AFF. Based on these
results, the authors concluded that AFFs have a polygenic
background. However, this study is also limited by a small
sample size and lack of functional studies to understand the
potential mechanisms leading to AFF.
Whole-exome sequencing
To date, only one study has been published on whole-exome
sequencing in patients with bisphosphonate-associated
AFFs(28) (Table 3). Exome sequencing may lead to the
discovery of yet unknown genetic variants related to the
risk of AFFs, although potential susceptibility variants for AFFs
in noncoding regions and regulatory areas of the genome may
still be missed.
In a recent letter to the editor by Roca-Ayats and
colleagues,(28) results were presented of a whole-exome
sequencing study in 3 sisters with bisphosphonate-associated
AFFs and in 3 unrelated patients with AFF after long-term
bisphosphonate treatment. Rare, protein-altering mutations
shared only by the 3 sisters were considered in this analysis. A
dominant model was assumed by the authors. In total, 37 rare
mutations were detected in 34 genes including a novelmissense
variant (p.Asp188Tyr) in geranylgeranyl diphosphate synthase 1
(GGPS1), a gene encoding for the enzyme geranylgeranyl
pyrophosphate synthase (GGPPS). GGPPS catalyzes the forma-
tion of geranylgeranyl pyrophosphate in the mevalonate
pathway. This novel variant is expected to severely impair
GGPPS enzyme activity, potentially impairing osteoclast func-
tion (Fig. 2). However, when themutation inGGPS1 is believed to
decrease osteoclast function, it might also be expected that the
siblings have a high bone mineral density and an osteopetrosis-
like phenotype, which is not evident from the case description in
this letter.
In addition, the authors describe a mutation of the gene
encoding CYP1A1 in the 3 sisters and in 1 unrelated patient with
AFF. Also, in 1 unrelated patient with an AFF, they identiﬁed a
mutation encoding mevalonate diphosphate decarboxylase
(MVD). Pathway analysis of the mutated genes showed
enrichment of the isoprenoid biosynthesis, which proceeds
through the mevalonate pathway in humans, including GGPS1,
CYP1A1, and MVD.
According to Roca-Ayats and colleagues, missense changes in
the FN1, SYDE2, and NGEF genes might also be relevant variants.
However, the authors do not discuss the potential mechanism
of action of these variants with regard to the pathophysiology of
AFFs. An overview of all found rare variants is not presented in
this letter. Replication of the novel GGPS1 mutation and the
other 36 genetic variants in other cases of AFFs could provide
evidence that 1 or more of these variants are potential
susceptibility genes for AFFs. Otherwise, several variants may
only be a result of shared DNA amongst the 3 siblings.
It is also possible that the GGPS1 is a private mutation in this
family and related to the underlying bone disease, not
necessarily to the AFFs. However, it is plausible that the
mutation is related to AFFs because the mevalonate pathway
is believed to be inhibited by bisphosphonates containing a
nitrogen side-chain, such as alendronate, risedronate, and
zoledronate. The novel GGPS1 variant would possibly disrupt a
binding site for magnesium of the GGPPS enzyme so that
binding of farnesyl pyrophosphate and catalysis are disturbed.
Blocking the farnesyl diphosphate synthase in this pathway
induces the apoptosis of osteoclasts, decreasing bone
resorption. In theory, this mutation could lead to a further
accumulation of the mevalonate pathway substrate, isopen-
tenyl pyrophosphate. In the literature, this substrate may
indirectly activate T lymphocytes and is considered the cause
of bisphosphonate-induced acute phase reaction in patients
on intravenous treatment.(81,82) It has been suggested that this
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mechanism may result in chronic immune stimulation and
compromised immunity in patients on long-term bisphosph-
onate therapy, which may contribute to another bisphosph-
onate-associated adverse event, such as osteonecrosis of the
jaw.(81,82)
Whole-exome sequencing in another family of AFFs was
presented in an abstract at the Australian New Zealand Bone &
Mineral Society Annual Meeting in 2017(29) (Table 3). Lau and
colleagues described a consanguineous family in whom three
siblings sustained bilateral AFFs without a history of bi-
sphosphonate exposure. Whole-exome sequencing of two
siblings revealed a novel homozygous variant in the splice
site of exon 6 of the cathepsin K gene (CTSK) (c.784þ3A>C), with
a variant frequency of 0.0000577. Mutations in CTSK are
associated with pycnodysostosis, and although the authors
reported that the proband had short stature and high bonemass
(T-scores of þ2.02 at the femoral neck and þ2.75 at the lumbar
spine), the proband had no other dysmorphic, clinical, or
radiographic features to suggest this condition. This ﬁnding
supports our hypothesis that individuals who sustain AFFs may
carry a rare variant associated with a monogenetic bone
disorder.
Conclusion
Although AFFs are rare fractures associated with antiresorptive
therapy, fear of this complication has been linked to the
poor uptake of this effective treatment for osteoporosis.
The pathogenesis of AFFs has not yet been elucidated, and
the future challenge lies in improving our understanding of the
association with antiresorptive therapy and the predisposing
risk factors, including genetic factors, in order to prevent these
fractures from occurring.
Here we summarize the evidence for genetic factors in AFFs.
These fractures can occur in patients with monogenetic bone
diseases, even without prior bisphosphonate exposure and in
some cases unmasking the underlying condition. Targeted
sequencing of some of these genes in AFF populations have
identiﬁed variants in CTSK, COL1A2, and ALPL genes, and we
propose that mild, unrecognized forms of such monogenetic
bone diseases may underlie the etiology of AFFs. Further,
whole-exome sequencing and exon array analysis of AFF
cohorts have identiﬁed novel genes that may predispose to
AFFs, including genes related to the mevalonate pathway.
These ﬁndings provide new insights into the pathogenesis of
AFF. It is important that these initial ﬁndings can be replicated
in future studies, in order to determine the exact genetic
architecture of this rare complication. Consequently, a simple
genetic test can be developed with all potential susceptibility
variants involved. This test could be used to screen patients
before prescribing (long-term) treatment with bisphospho-
nates or denosumab.
Identiﬁcation of susceptibility genes predisposing to AFFs
may provide a solution in detecting patients at greatest risk of
AFFs by genetic testing, for whom alternative anabolic
treatment should be recommended. To date, genetic studies
in AFF cases have comprised small cohorts. An international,
multicentered collaborative study of well-phenotyped AFF cases
and controls is needed to detect rare variants associated with
AFFs, as well as common variants in multiple genes. This would
enable future targeting of antiresorptive therapy to those with
low AFF risk.
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